JP2012532891A5 - - Google Patents

Download PDF

Info

Publication number
JP2012532891A5
JP2012532891A5 JP2012519794A JP2012519794A JP2012532891A5 JP 2012532891 A5 JP2012532891 A5 JP 2012532891A5 JP 2012519794 A JP2012519794 A JP 2012519794A JP 2012519794 A JP2012519794 A JP 2012519794A JP 2012532891 A5 JP2012532891 A5 JP 2012532891A5
Authority
JP
Japan
Prior art keywords
composition
individual
vitamin
thyroid
iron
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012519794A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012532891A (ja
JP5940448B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/041631 external-priority patent/WO2011006147A1/en
Publication of JP2012532891A publication Critical patent/JP2012532891A/ja
Publication of JP2012532891A5 publication Critical patent/JP2012532891A5/ja
Application granted granted Critical
Publication of JP5940448B2 publication Critical patent/JP5940448B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012519794A 2009-07-10 2010-07-09 甲状腺関連の医学的状態を還元葉酸によって処置するための方法および組成物 Active JP5940448B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US27061509P 2009-07-10 2009-07-10
US61/270,615 2009-07-10
US27074109P 2009-07-13 2009-07-13
US61/270,741 2009-07-13
PCT/US2010/041631 WO2011006147A1 (en) 2009-07-10 2010-07-09 Methods and compositions for treating thyroid-related medical conditions with reduced folates

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015232702A Division JP2016047840A (ja) 2009-07-10 2015-11-30 甲状腺関連の医学的状態を還元葉酸によって処置するための方法および組成物

Publications (3)

Publication Number Publication Date
JP2012532891A JP2012532891A (ja) 2012-12-20
JP2012532891A5 true JP2012532891A5 (enExample) 2013-08-29
JP5940448B2 JP5940448B2 (ja) 2016-06-29

Family

ID=43427658

Family Applications (6)

Application Number Title Priority Date Filing Date
JP2012519794A Active JP5940448B2 (ja) 2009-07-10 2010-07-09 甲状腺関連の医学的状態を還元葉酸によって処置するための方法および組成物
JP2015232702A Withdrawn JP2016047840A (ja) 2009-07-10 2015-11-30 甲状腺関連の医学的状態を還元葉酸によって処置するための方法および組成物
JP2017142887A Withdrawn JP2017186383A (ja) 2009-07-10 2017-07-24 甲状腺関連の医学的状態を還元葉酸によって処置するための方法および組成物
JP2019054748A Withdrawn JP2019089858A (ja) 2009-07-10 2019-03-22 甲状腺関連の医学的状態を還元葉酸によって処置するための方法および組成物
JP2021043527A Withdrawn JP2021091739A (ja) 2009-07-10 2021-03-17 甲状腺関連の医学的状態を還元葉酸によって処置するための方法および組成物
JP2023045339A Withdrawn JP2023068107A (ja) 2009-07-10 2023-03-22 甲状腺関連の医学的状態を還元葉酸によって処置するための方法および組成物

Family Applications After (5)

Application Number Title Priority Date Filing Date
JP2015232702A Withdrawn JP2016047840A (ja) 2009-07-10 2015-11-30 甲状腺関連の医学的状態を還元葉酸によって処置するための方法および組成物
JP2017142887A Withdrawn JP2017186383A (ja) 2009-07-10 2017-07-24 甲状腺関連の医学的状態を還元葉酸によって処置するための方法および組成物
JP2019054748A Withdrawn JP2019089858A (ja) 2009-07-10 2019-03-22 甲状腺関連の医学的状態を還元葉酸によって処置するための方法および組成物
JP2021043527A Withdrawn JP2021091739A (ja) 2009-07-10 2021-03-17 甲状腺関連の医学的状態を還元葉酸によって処置するための方法および組成物
JP2023045339A Withdrawn JP2023068107A (ja) 2009-07-10 2023-03-22 甲状腺関連の医学的状態を還元葉酸によって処置するための方法および組成物

Country Status (26)

Country Link
US (13) US8343974B2 (enExample)
EP (2) EP3053583B1 (enExample)
JP (6) JP5940448B2 (enExample)
KR (1) KR101850558B1 (enExample)
CN (2) CN102639009B (enExample)
AP (1) AP2012006124A0 (enExample)
AU (1) AU2010271178B2 (enExample)
BR (1) BR112012000614B1 (enExample)
CA (2) CA2804265C (enExample)
DK (1) DK2451299T3 (enExample)
EA (1) EA201270160A1 (enExample)
ES (1) ES2569238T3 (enExample)
HR (1) HRP20160406T1 (enExample)
HU (1) HUE027341T2 (enExample)
IL (3) IL304064A (enExample)
IN (1) IN2012DN01286A (enExample)
MX (2) MX2012000535A (enExample)
MY (2) MY181956A (enExample)
NZ (1) NZ598171A (enExample)
PH (2) PH12022552212A1 (enExample)
PL (1) PL2451299T3 (enExample)
SG (2) SG10201404000RA (enExample)
SI (1) SI2451299T1 (enExample)
SM (1) SMT201600110B (enExample)
WO (1) WO2011006147A1 (enExample)
ZA (2) ZA201201002B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20160406T1 (hr) * 2009-07-10 2016-05-20 Linzy O. Scott Iii Postupci i pripravci za liječenje sa štitnjačom povezanih medicinskih stanja sa sniženiim folatima
US20140271704A1 (en) * 2013-03-15 2014-09-18 Jarrow Formulas, Inc. METHODS OF PRODUCING NUTRITIONAL SUPPLEMENTS USING MUSHROOMS FROM THE SPECIES Poria cocos OR Flammulina velutipes
US20160053281A1 (en) 2013-08-15 2016-02-25 The University Court Of The University Of Edinburgh Enhanced Expression Of RNA Vectors
CN103705497B (zh) * 2013-12-11 2015-04-01 武汉威立得生物医药有限公司 碘塞罗宁在制备治疗或预防流感病毒感染的药物中的应用
JP6424078B2 (ja) * 2014-02-13 2018-11-14 山洋電気株式会社 ステータ、ステータの製造方法、およびモータ
CN108992458A (zh) * 2018-06-12 2018-12-14 中国人民解放军第四军医大学 维生素b12用于制备预防和/或治疗术后认知功能障碍药物的应用
EP4138809A4 (en) * 2020-04-22 2024-05-01 Scott III, Linzy O. TREATMENT OF DISEASES RELATED TO THYROID HORMONE
CN116887702A (zh) * 2020-07-27 2023-10-13 乔治·阿尤布 降低脑叶酸缺乏症的发病率或风险的方法
WO2022208216A1 (en) * 2021-03-31 2022-10-06 Boggarapu, Shravya An oral liquid formulation of metformin, teneligliptin, vitamin b12, atorvastatin and levothyroxine for diabetes

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4205126A (en) * 1978-01-01 1980-05-27 Cartaya Oscar A Serum-free cell culture media
US5563126A (en) 1986-11-20 1996-10-08 Metabolite Laboratories Method for treatment and prevention of deficiencies of vitamins B12, folic acid, and B6
IT1229517B (it) 1989-01-31 1991-09-03 Bioresearch Spa Impiego di acido 5-metiltetraidrofolico, di acido 5 formiltetraidrofolico, e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato adatte ad essere impiegate nella terapia dei disordini depressivi e composizioni farmaceutiche relative.
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
GB9022545D0 (en) 1990-10-17 1990-11-28 Wellcome Found Culture medium
US5591709A (en) 1991-08-30 1997-01-07 Life Medical Sciences, Inc. Compositions and methods for treating wounds
US6207651B1 (en) 1996-08-02 2001-03-27 Metabolite Laboratories Method for treatment and prevention of deficiencies of vitamins B12, folic acid, and B6
US5795873A (en) 1992-12-29 1998-08-18 Metabolite Laboratories, Inc. Method for treatment and prevention of deficiencies of vitamins B12, folic acid and B6
US6455288B1 (en) 1993-04-08 2002-09-24 Dade Behring Marburg Gmbh Homogeneous immunoassays using mutant glucose-6-phosphate dehydrogenases
CH686369A5 (de) 1994-05-09 1996-03-15 Eprova Ag Stabile kristalline (6S)- und (6R)-Tetrahydrofolseure.
US5681561A (en) 1995-06-07 1997-10-28 Life Medical Sciences, Inc. Compositions and methods for improving autologous fat grafting
ATE262799T1 (de) 1996-01-31 2004-04-15 Univ South Alabama Lebensmittel und vitamin herstellungen mit natürlichem isomeren von reduzierten folaten
CH693255A5 (de) 1997-06-13 2003-05-15 Eprova Ag Verwendung von Tetrahydrofolaten in der natürlichenstereoisomeren Form zur Herstellung einer pharmazeutischenZubereitung geeignet zur Beeinflussung des Homocystein-Spiegels.
US6200950B1 (en) 1998-02-18 2001-03-13 Nestec S.A. Calorically dense nutritional composition
US6153582A (en) 1998-11-05 2000-11-28 Bausch & Lomb Surgical, Inc. Defined serumfree medical solution for ophthalmology
WO2000040749A2 (en) 1999-01-06 2000-07-13 Genenews Inc. Method for the detection of gene transcripts in blood and uses thereof
DE60011877D1 (de) 1999-01-19 2004-08-05 Lidia M Vallarino Reaktionssystem und verfahren zur verstärkung der lumineszenz von makrocyclischen lanthanid(iii)-komplexen
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
WO2000061154A1 (en) * 1999-04-08 2000-10-19 Khan Airudin S Composition, containing sublimed sulphur, for altering plasma homodyst(e) levels in humans
CH693905A5 (de) 1999-04-15 2004-04-15 Eprova Ag Stabile kristalline Salze von 5-Methyltetrahydrofolsäure.
US8383081B2 (en) 1999-05-10 2013-02-26 Immunomedics, Inc. Anti-CD74 immunoconjugates and methods of use
US6309663B1 (en) 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
US6720001B2 (en) 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
US20020042386A1 (en) 2000-01-31 2002-04-11 Rosen Craig A. Nucleic acids, proteins, and antibodies
EP1372571A4 (en) 2001-03-20 2006-06-07 New Century Pharmaceuticals METHOD AND COMPOSITIONS FOR OPTIMIZING THE STABILITY OF BLOOD AND TISSUES CONFERRED BY CAMPTOTHECIN AND OTHER THERAPEUTIC COMPOUNDS BINDING ALBUMIN
US6506413B1 (en) 2001-04-30 2003-01-14 Joseph C. Ramaekers Compositions for treating animal diseases and syndromes
US20080220441A1 (en) 2001-05-16 2008-09-11 Birnbaum Eva R Advanced drug development and manufacturing
AU2002322275A1 (en) 2001-06-20 2003-01-08 Mayo Foundation For Medical Education And Research Adenosyl-cobalamin fortified compositions
US6660293B2 (en) 2001-06-29 2003-12-09 Everett Laboratories, Inc. Compositions and methods for prophylactic and therapeutic supplementation of nutrition in subjects
US20030195253A1 (en) 2001-08-14 2003-10-16 Franz G. Andrew Unadsorbed levothyroxine pharmaceutical compositions, methods of making and methods of administration
WO2003068223A1 (en) 2002-02-11 2003-08-21 Bayer Corporation Aryl ureas with raf kinase and angiogenesis inhibiting activity
US7074426B2 (en) 2002-03-27 2006-07-11 Frank Kochinke Methods and drug delivery systems for the treatment of orofacial diseases
US20030233035A1 (en) 2002-06-12 2003-12-18 Surromed, Inc. Methods and devices for diagnosing and treating choroid plexus failure
EP1581648A2 (en) 2002-09-09 2005-10-05 Nura, Inc. G protein coupled receptors and uses thereof
KR20050065587A (ko) 2002-10-08 2005-06-29 이뮤노메딕스, 인코오포레이티드 항체 치료법
CA2509382A1 (en) 2002-12-17 2004-07-08 Todd C. Zion Stimuli-responsive systems for controlled drug delivery
US20050031651A1 (en) 2002-12-24 2005-02-10 Francine Gervais Therapeutic formulations for the treatment of beta-amyloid related diseases
WO2004092334A2 (en) * 2003-04-09 2004-10-28 Jarrow Formulas, Inc. Methods of producing edible fungi containing activated folates and nutritional supplements containing activated folates
US7517342B2 (en) 2003-04-29 2009-04-14 Boston Scientific Scimed, Inc. Polymer coated device for electrically medicated drug delivery
US20050031544A1 (en) 2003-08-07 2005-02-10 Njemanze Philip Chidi Receptor mediated nanoscale copolymer assemblies for diagnostic imaging and therapeutic management of hyperlipidemia and infectious diseases
US8388949B2 (en) 2003-12-24 2013-03-05 N.V. Nutricia Compositions comprising pantothenic acid and their use for stimulating appetite
US20060211752A1 (en) 2004-03-16 2006-09-21 Kohn Leonard D Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression
US7838524B2 (en) 2004-04-30 2010-11-23 Bayer Healthcare Llc Substituted pyrazolyl urea derivatives useful in the treatment of cancer
US20100087546A1 (en) 2005-04-20 2010-04-08 Biogenic Innovations, Llc Use of dimethyl sulfone (msm) to reduce homocysteine levels
US20060252049A1 (en) 2005-05-04 2006-11-09 Shuler Richard O Growth-promoting and immunizing subcutaneous implant
WO2006119589A2 (en) 2005-05-11 2006-11-16 Ramaekers, Vincent Prevention and therapy of cerebral folate deficiency
AU2006262096B2 (en) 2005-06-21 2012-11-01 Children's Hospital & Research Center At Oakland Methods and compositions containing natural folates for protecting against radiation damage
RU2005128993A (ru) 2005-09-08 2007-03-20 Общество С Ограниченной Ответственностью Исследовательский Центр "Комкон" (Ru) Средство для коррекции стресс-индуцируемых нейромедиаторных, нейроэндокринных и метаболических нарушений, а также способ профилактики и лечения сопутствующих им паталогических состояний
JP5713534B2 (ja) 2005-10-07 2015-05-07 ザ ユニバーシティ オブ アラバマ 多機能イオン性液体組成物
US20070243132A1 (en) 2005-12-22 2007-10-18 Apollo Life Sciences Limited Transdermal delivery of pharmaceutical agents
US8524454B2 (en) 2006-04-07 2013-09-03 The Research Foundation Of State University Of New York Transcobalamin receptor polypeptides, nucleic acids, and modulators thereof, and related methods of use in modulating cell growth and treating cancer and cobalamin deficiency
US20080066739A1 (en) 2006-09-20 2008-03-20 Lemahieu Edward Methods and systems of delivering medication via inhalation
US20090088404A1 (en) 2007-01-31 2009-04-02 Methylation Sciences International Srl Extended Release Pharmaceutical Formulations of S-Adenosylmethionine
US20100304418A1 (en) 2007-12-17 2010-12-02 Artin Moussavi Compositions and Methods for Monitoring Flow Through Fluid Conducting and Containment Systems
HRP20160406T1 (hr) * 2009-07-10 2016-05-20 Linzy O. Scott Iii Postupci i pripravci za liječenje sa štitnjačom povezanih medicinskih stanja sa sniženiim folatima

Similar Documents

Publication Publication Date Title
IL304064A (en) Methods and compositions for the treatment of diseases related to the thyroid gland, with a reduced amount of folates
HRP20241016T1 (hr) Inhibitori tyk2 i njihova uporaba
HRP20200777T1 (hr) Formulacije koje sadrže triazinone i željezo
JP2017507973A5 (enExample)
HRP20230809T1 (hr) Liječenje alzheimerove bolesti u određenoj populaciji bolesnika
BR112012019374A2 (pt) composição farmacêutica, pellet de liberação prolongada, composição farmacêutica oral, método para tratamento de uma doença neurodegenerativa ou um dano ao sistema nervoso em um indivíduo necessitado do mesmo e método para preparação de uma formulação de liberação prolongada de um agente ativo
JP2013231087A5 (enExample)
RU2010136914A (ru) Средство и продукт питания для профилактики/уменьшения проявлений функционального расстройства пищеварения
BR112012026223A2 (pt) formulação adequada para o uso em ração animal, uso, e ração para animais.
JP2010522240A (ja) 炎症を処置するための組成物および方法
JP2017535616A5 (enExample)
ZA201901370B (en) Formulations for oral administration of active agents
Saeed et al. Lead poisoning: A persistent health hazard-general and oral aspects
DE102007053369A1 (de) Verwendung einer eine Kreatin-Komponente enthaltende Zusammensetzung zur Verbesserung der männlichen Fruchtbarkeit
HRP20230735T1 (hr) Betahistin, ili njegova farmaceutski prihvatljiva sol, i inhibitor monoamin oksidaze, za uporabu u liječenju ili prevenciji jednog ili više simptoma vrtoglavice kod subjekta
PH12022553005A1 (en) Composition for the prevention and treatment of folate and/or vitamin b12 deficiency conditions, particularly hyperhomocysteinemia
BRPI0715609A2 (pt) Composto, uso de um composto, métodos para produzir um efeito antiproliferativo em um animal de sangue quente, e para tratar uma doença em um animal de sangue quente, e, composição farmacêutica
JP2016210757A5 (enExample)
EA023535B9 (ru) Композиция водного радиопротекторного фармацевтического раствора и способ предотвращения, снижения или исключения эффектов ионизирующей радиации
UA90893C2 (ru) Пероральная дозированная форма производных гемцитабина
AU2018251094B2 (en) Compositions and methods that attenuate cognitive aging in individuals who do not have dementia
JP2017012144A5 (enExample)
EA200900077A1 (ru) Противоопухолевая, антибактериальная и антивирусная фармацевтическая композиция (ее варианты)
WO2021151442A3 (en) Methotrexate dosage form
Dickson et al. The premature invocation of a ‘gut-lung axis’ may obscure the direct effects of respiratory microbiota on pneumonia susceptibility